NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization405.43 mln
Float58.46 mln
Earnings Date08/06/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
3.50
Downside risk
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.36
Low leverage
ROE
-92.13
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Replimune Group is a biotechnology company focused on developing cancer treatments that use modified viruses to trigger the body's immune system to fight tumors. Founded in 2015 and based in Woburn, Massachusetts, the company has several therapies in development, with its most advanced candidate targeting a broad range of solid tumors. Its pipeline also includes treatments designed to further strengthen the immune response by blocking proteins that would otherwise suppress it or by directly stimulating key immune cells.
